People with Treatment Resistant Late-Life Depression (TRLLD) are at very high risk for suicide (including suicidal ideation and/or behavior) as well as neurocognitive impairment and decline to dementia. This proposed Administrative Supplement leverages our funded R01 ?Neurocognitive and Neuroimaging Biomarkers: Predicting Progression Towards Dementia in Patients with Treatment Resistant Late-Life Depression? (OPTIMUM-Neuro) to examine the relationship between suicide risk and brain health in a large group of patients with TRLLD. Additional measures of suicide risk (lifetime history of and current suicidal ideation and behavior) will be obtained and neurocognitive diagnosis will be adjudicated using expert consensus conferences for the 300 participants already recruited in OPTIMUM-Neuro as of May 2019 and an additional 150 recruited over the supplement's one-year time frame. The data will be used to examine both history of suicidal ideation and behavior (collected through this supplement) and trajectories of suicidal ideation and behavior over one year (collected through this supplement during the OPTIMUM-Neuro follow-up time period).
The aims of the proposed research will examine in people with TRLLD (1) whether assessing and including information about neurocognitive functioning improves our prediction of suicide risk and whether a novel measure of real-life decision-making (through the Research Domain Criteria (RDoC) framework) adds to our ability to predict one's suicide risk; (2) whether early-onset and late-onset suicidal ideation and/or risk are associated with specific and different neurocognitive impairments; and (3) whether risk of suicide is higher in people with TRLLD and a diagnosis of Mild Cognitive Impairment than in those with no cognitive diagnosis, and whether it is especially high in those whose impairment is caused by cerebrovascular disease, as compared with Alzheimer's disease. In sum, OPTIMUM-Neuro provides a unique opportunity to examine the relationship between suicide risk and cognitive impairment and decline in a large and well-characterized longitudinal study of community-dwelling older individuals particularly vulnerable to both suicidal behavior and dementia due to TRLLD.

Public Health Relevance

Older adults with Major Depression that does not improve with the most common treatments are at very high risk for suicide (including suicidal ideation and/or behavior) as well as impairment in thinking and memory and decline to dementia. This Supplement Study will take advantage of our already funded and ongoing study focused on depression and dementia and expand it to examine whether knowing about cognitive impairment improves our ability to predict suicide risk, whether knowing when people first thought about or attempted suicide is related to different thinking and memory problems, and whether particular medical diagnoses related to cognitive impairments and their causes, increase risk of suicide.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
3R01MH114969-03S1
Application #
9940089
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Rowland, Laura Marie
Project Start
2017-09-18
Project End
2022-07-31
Budget Start
2019-09-01
Budget End
2020-07-31
Support Year
3
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Psychiatry
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15260